No Data
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Regeneron Gains 13.5% Year to Date: How to Play the Stock?
Pharmaceutical company warns: if muscle loss issue is not addressed, 'miracle weight-loss drugs' may do more harm than good.
①USA pharmaceutical company Regeneron stated that current GLP-1 weight loss drugs can lead to rapid muscle loss, and the company is developing a weight loss drug that can overcome this flaw; ② Regeneron warned that if the muscle loss issue is not resolved, GLP-1 weight loss drugs may do more harm than good.
Regeneron Sees $56M Pretax Charge Hitting 3Q Earnings
Regeneron Sees IPR&D Impact of About $0.43/share on Q3 Income